Shares of Akebia Therapeutics AKBA surged 24% after the company reported Q1 results.
Quarterly Results
Earnings per share fell 6.82% year over year to ($0.47), which beat the estimate of ($0.62).
Revenue of $88,478,000 up by 21.76% year over year, which beat the estimate of $77,480,000.
Looking Ahead
Akebia Therapeutics hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: May 05, 2020
Time: 01:05 PM ET
Webcast URL: https://edge.media-server.com/mmc/p/tni8ok36
Price Action
52-week high: $10.53
Company's 52-week low was at $2.99
Price action over last quarter: Up 24.78%
Company Overview
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
